The AI assessment is bullish with medium confidence. The strong analyst support and the company's differentiated pipeline targeting disease modification in psoriasis provide a compelling growth narrative. The recent capital raise addresses liquidity concerns, and the stock's momentum suggests positive market sentiment. However, the lack of revenue and the high valuation relative to clinical-stage peers introduce significant uncertainty. The stance would be upgraded to high confidence if early clinical data shows best-in-class efficacy, and downgraded to neutral if a trial fails or dilution is excessive. Overall, the risk-reward is favorable for investors with a high risk tolerance, but the medium confidence reflects the binary nature of clinical-stage biotech investing.

Given that Oruka has negative net income, the price-to-sales ratio is not applicable (PS ratio = 0). Therefore, I selected the price-to-book (PB) ratio as the primary valuation metric, which is 2.93. This is a common approach for clinical-stage biotechs with no revenue. The trailing PE is -13.12 and forward PE is -38.73, both negative, reflecting expected continued losses. The PB ratio of 2.93 is below the historical average of around 5.5 from Q1 2026, suggesting the stock is trading at a discount to its recent book value multiple. However, the company's book value is largely cash, and the market is pricing in significant future value from its pipeline. Compared to the industry average PB for biotech (typically 3-5x), Oruka's 2.93x is at a discount, which may be justified by its early-stage status and lack of revenue. Historically, the PB ratio has ranged from 0.61 to 20.31 over the past five years, with the current level near the lower end, indicating that the market is not overly exuberant on a book value basis, despite the stock's price surge.